
Biogen Inc
BIIB · NASDAQ · Healthcare / Drug Manufacturers - General
Price History
Full chartMarket Stats
About
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Company Details
- SectorHealthcare
- IndustryDrug Manufacturers - General
- CEOMr. Christopher A. Viehbacher
- Employees7.50K
- Headquarters225 Binney Street, Cambridge, MA, United States, 02142, USA
- Websitehttps://www.biogen.com
Leadership
- Mr. Christopher A. ViehbacherPresident, CEO & Director · b. 1961
- Ms. Robin C. KramerExecutive VP & CFO · b. 1966
- Ms. Nicole MurphyExecutive VP and Head of Pharmaceutical Operations & Technology · b. 1973
- Dr. Priya Singhal M.D., M.P.H.Executive VP & Head of Development · b. 1968
- Mr. Sean GodboutVP, Chief Accounting Officer & Global Corporate Controller · b. 1974
- Mr. Guy HadariChief Information Officer
- Mr. Tim Power M.B.A., Ph.D.Head of Investor Relations
- Mr. Michael John Parini J.D.Chief Legal Officer · b. 1974
- Ms. Natacha GassenbachChief Communication Officer & Head of Corporate Affairs
- Mr. Adam Keeney Ph.D.Executive VP & Head of Corporate Development · b. 1977
Financials
Income Statement
Balance Sheet
Cash Flow
Earnings
Key Statistics & Ratios
Analyst Ratings
- Strong Buy21
- Buy4
- Hold10
- Strong Sell1
Ownership Breakdown
- Institutions
- 100.07%
- Insiders
- 0.19%
- Retail / Other
- 0.00%
Top Institutional Holders
- FMR Inc18.22M12.32%
- BlackRock Inc15.99M10.81%
- PRIMECAP Management Company15.15M10.25%
- Vanguard Capital Management, LLC9.65M6.53%
- State Street Corp7.34M4.97%
- Vanguard Portfolio Management, LLC6.60M4.47%
- Geode Capital Management, LLC4.45M3.01%
- Wellington Management Company LLP3.12M2.11%
- NORGES BANK2.58M1.75%
- Morgan Stanley - Brokerage Accounts2.41M1.63%
- AQR Capital Management LLC1.94M1.31%
Top Fund Holders
- Vanguard PRIMECAP Inv8.36M5.66%
- Fidelity Contrafund5.23M3.54%
- Vanguard MStar Total Stk Mkt Idx Invest4.68M3.17%
- Vanguard 500 Index Investor3.88M2.63%
- Vanguard MStar Mid Cap Index Instl3.16M2.14%
- Vanguard Health Care Inv2.75M1.86%
- Vanguard Capital Opportunity Inv2.62M1.78%
- Fidelity Canadian Large Cp Mlt Ast Bs O2.31M1.56%
- iShares Core S&P 500 ETF1.97M1.33%
Stock Splits
- Jan 18, 20013:1
- Dec 21, 19992:1